Deep vein thrombosis (DVT) leads to venous ulcers in later life. Venous ulcers are the majority of chronic lower extremity wounds. Recent evidence suggests that hyperhomocysteinemia is an independent risk factor for venous thrombosis. Other evidence suggests that dietary supplementation with folic acids and vitamins helps to change hyper-homocysteinemia. This may be the key to wound management in the future.
Toborek M, Kopieczna-Grzebieniak E, Dródz M, et al.Increased lipid peroxidation as a mechanism of methionine-induced atherosclerosis in rabbits. Atherosclerosis1995;115:217-224.
2.
Welch GW, Loscalzo J.Homocysteine and atherosclerosis. N Engl J Med1998;338:1042-1050.
3.
Ubbink JB.Homocysteine—an atherogenic and a thrombogenic factor?Nutr Rev1995;53:323-325.
4.
Mudd SH, Skovby F, Levy HL, et al.The natural history of homocysteinuria due to cystathione β-synthase deficiency. Am J Hum Genet1985;37:1-31.
5.
den Heijer M, Kostor T, Blom HJ, et al.Homocysteinemia as a risk factor for deep vein thrombosis. N Engl J Med1996;334:759-762.
Willems HP, den Heijer M, Bos GM.Homocysteine and venous thrombosis: outline of a vitamin intervention trial. Semin Thromb Hemost2000;26:297-304.
8.
Langman LJ, Ray JG, Evrovski J, et al.Hyperhomocyst(e)inemia and increased risk of venous thromboembolism: more evidence from case-control study. Arch Intern Med2000;160:961-964.
9.
D’Angelo A, Selhub J.Homocysteine and thrombotic disease. Blood1997;90:1-11.
10.
Ueland PM, Refsum H.Review article: plasma homocysteine, a risk factor for vascular disease, plasma levels in health, disease and drug therapy. J Lab Clin Med1989;114:473-501.
11.
Boushey CJ, Beresford SAA, Omenn GS, et al.A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J Am Med Assoc1995;274:1049-1057.
12.
Mayer EM, Jacobsen DW, Robinson K.Homocysteine and coronary atherosclerosis. J Am Coll Cardiol1996;27:517-527.
13.
Bertina RM, Koeleman BP, Koster T, et al.Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature1994;369:64-67.
14.
Port SR, Rosendaal FR, Reitsma PH, et al.A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood1996;88:3698-3703.
15.
Egeberg O.Inherited antithrombin III deficiency causing thrombophilia. Thromb Diath Haemorrh1965;13:516-530.
16.
Griffin JH, Evatt BL, Zimmerman TS, et al.Deficiency of protein-c in congenital thrombotic disease. J Clin Invest1981;68:1370-1373.
17.
Allaart CF, Poort SR, Rosendaal FR, et al.Increased risk of venous thrombosis in carriers of hereditary protein-c deficiency defect. Lancet1993;341:134-138.
18.
Zöller B, Berntsdottes A, Garcia de Fructos P, et al.Resistance to activated protein C as the additional genetic risk factor in hereditary deficiency of protein S. Blood1995;85:3518-3523.
19.
Koster T, Rosendaal FR, Reitsma PH, et al.Factor VII and fibrinogen levels as risk factors for venous thrombosis: a case-control study of plasma levels and DNA polymorphisms: the Leiden Thrombophilia Study (LETS). Thromb Haemost1994;71:719-722.
Koster T, Blann AD, Briët E, et al.Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep vein thrombosis. Lancet1995;345:152-155.
22.
Kraaijenhagen RA, Anker PS, Koopman MM, et al.High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost2000;83:5-9.
23.
Ueland PM, Refsum H, Stabler SP, et al.Total homocysteine in plasma or serum. Methods and clinical application. Clin Chem1993;39:1764-1779.
24.
Kang S-S, Wong PWK, Norusis M.Homocysteinemia due to folate deficiency. Metabolism1987;36:458-462.
25.
Kang S-S, Wong PWK, Cook HY, et al.Protein-bound homocyst(e)ine: a possible risk factor for coronary artery disease. J Clin Invest1986;77:1482-1486.
26.
Kang S-S, Wong PWK, Malinow MR.Hyperhomocysteinemia as a risk factor for occlusive vascular disease. Annu Rev Nutr1992;12:279-298.
27.
Prasad K.Homocysteine, a risk factor for cardiovascular disease. Int J Angiol1999;8:76-86.
28.
Mudd SH, Levy HL, Skovby F.Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, et al, editors. The metabolic and molecular basis of inherited disease. New York: McGraw-Hill; 1995. p. 1279-1327.
29.
Ballal RS, Jacobson DW, Robinson K.Homocysteine: update on a new risk factor. Cleveland Clin J Med1997;64:543-549.
30.
Kang S-S, Zhou J, Wong PWK, et al.Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet1988;43:414-421.
31.
Miller JW, Ribayamercado JD, Russell RM, et al.Effect of vitamin B6 deficiency on fasting plasma homocysteine concentrations. Am J Clin Nutr1992;55:1154-1160.
32.
Allen RH, Stabler SP, Savage DG, et al.Metabolic abnormalities in cobalamin (vitamin B12) and folate deficiency. FASEB J1994;7:1344-1353.
33.
Selhub J, Jacques PF, Wilson PWF, et al.Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA1993;270:2693-2698.
34.
Wight TN.Vessel proteoglycans and thrombogenesis. In: Spact TH, editor. Progress in hemostasis and thrombosis. New York: Grume & Stratton; 1980. p. 1-39.
35.
Esmon CT, Owen WG.Identification of endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci U S A1981;78:2249-2252.
36.
Weksler BB, Marcus AJ, Jaffe EA.Synthesis of prostaglandin I2 (prostacyclin) by cultured human and bovine endothelial cells. Proc Natl Acad Sci U S A1977;74:3922-3926.
37.
Loskuttoff DJ, Edgington TS.Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. Proc Natl Acad Sci U S A1977;74:3903-3907.
38.
Di Minno G, Davi G, Margaglione M, et al.Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest1993;92:1400-1408.
39.
Graeber JE, Slott JH, Ulane RE, et al.Effect of homocysteine and homocysteine on platelet and vascular arachidonic acid metabolism. Pediatr Res1982;16:490-493.
40.
Mudd SH, Levy HL.Disorders of transulfuration. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, et al, editors. The metabolic basis of inherited disease. 5th ed.New York: McGraw-Hill; 1983. p. 522-559.
41.
McDonald L, Bray C, Field C, et al.Homocystinuria, thrombosis, and the blood-platelets. Lancet1964;1:745-746.
42.
Rodgers GM, Kane WH.Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest1986;77:1909-1916.
43.
Kane WH, Majerus PW.Purification and characterization of human coagulation factor V. J Biol Chem1981;256:1002-1007.
44.
Ratnoff OD.Activation of Hageman factor by L-homocysteine. Science1968;162:1007-1009.
45.
Lenz SR, Sadler JE.Homocysteine inhibits von Willebrand factor processing and secretion by preventing transport from the endoplasmic reticulum. Blood1993;81:683-689.
46.
Kamphuisen PW, Eikenboom JCJ, Bertina RM.Elevated factor VIII levels and risk of thrombosis. Arterioscler Thromb Vasc Biol2001;21:731-737.
47.
Heinecke JW, Rosen H, Suzuki LA, et al.The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem1987;262:10098-10103.
48.
Olszewski AJ, McCully KS.Homocysteine metabolism and the oxidative modification of proteins and lipids. Free Radic Biol Med1993;14:683-693.
49.
Stamler JS, Osborne JA, Jaraki O, et al.Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest1993;91:308-318.
50.
Welch GN, Upchurch GR, Keaney JF, et al.Homocyst(e)ine decreases cell redox potential in vascular smooth muscle cells. J Am Coll Cardiol1996;27(Suppl A):163A. Abstract.
51.
Misra HP.Generation of superoxide free radical during auto-oxidation of thiols. J Biol Chem1974;249:2151-2155.
52.
Rowley DA, Halliwell B.Superoxide-dependent formation of hydroxyl radicals in the presence of thiol compounds. FEBS Lett1982;138:33-36.
53.
Lang D, Kredan MB, Moat SJ, et al.Homocysteine-induced inhibition of endothelium-dependent relaxation in rabbit aorta. Arterioscler Thromb Vasc Biol2000;20:422-427.
54.
Polack B, Pernod G, Barro C, et al.Role of oxygen radicals in tissue factor induction by endotoxin in blood monocytes. Haemostasis1997;27:193-200.
55.
Shatos MA, Doherty JM, Orfeo T, et al.Modulation of the fibrinolytic response of cultured human vascular endothelium by extracellularly generated oxygen radicals. J Biol Chem1992;267:597-601.
56.
Jourdan A, Aguejouf O, Imbault P, et al.Experimental thrombosis model induced by free radicals: application to aspirin and other different substances. Thromb Res1995;79:109-123.
57.
Hayashi T, Honda TG, Suzuki K.An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood1992;79:2930-2936.
58.
Rodgers GM, Conn MT.Homocysteine, an atherogenic stimulus, reduces protein c activation by arterial and venous endothelial cells. Blood1990;75:895-901.
59.
Lenz SR, Sadler JE.Inhibition of thrombomodulin surface expression and protein-c activation by thrombogenic agent homocysteine. J Clin Invest1991;88:1906-1914.
60.
Nishinaga M, Ozawa T, Shimada K.Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest1993;92:1381-1386.
61.
Hajjar KA.Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest1993;91:2873-2879.
62.
Harker LA, Ross R, Slichter SJ, et al.Homocysteine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. J Clin Invest1976;58:731-741.
63.
Wall RT, Harlan LM, Harker LA, et al.Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res1980;18:113-121.
64.
Blundell G, Jones BG, Rose FA, et al.Homocysteine mediated endothelial cell toxicity and its amelioration. Atherosclerosis1996;122:163-172.
65.
Anderson FA, Wheeler HB, Goldberg RJ, et al.A population based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worchester DVT Study. Arch Intern Med1991;151:933-938.
66.
Nordstrom M, Lindblad B, Bergquist D, et al.A prospective study of the incidence of deep vein thrombosis within a defined urban population. J Intern Med1992;232:155-160.
67.
Lee JCL, Spittell JA, Sauer WG, et al.Hypercoagulability associated with chronic ulcerative colitis: changes in blood coagulation factors. Gastroenterol1968;54:76-85.
68.
Koster T, Rosendaal FR, Briet E, et al.Protein-c deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood1995;85:2756-2761.
69.
Rosendaal FR, Koster T, Vandenbrouke JP, et al.High risk of thrombosis in patients homozygous for factor V Leiden (activated protein-c resistance). Blood1995;85:1504-1508.
70.
Schimke RN, McKusick VA, Huang T, et al.Homocystinuria: studies of 20 families with 38 affected members. JAMA1965;193:711-719.
71.
Carson NAJ, Neill DW.Metabolic abnormalities detected in a survey of mentally backward individuals in Northern Ireland. Arch Dis Child1962;37:505-513.
Bienvenu T, Ankri A, Chadefaux B, et al.Elevated total plasma homocysteine, a risk factor for thrombosis. Relation to coagulation and fibrinolytic parameters. Thromb Res1993;70:123-129.
74.
Brattstrom L, Tengborn L, Lagerstedt C, et al.Plasma homocysteine in venous thromboembolism. Haemostasis1991;21:51-57.
75.
Falcon CR, Cattaneo M, Panzeri D, et al.High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb1994;14:1080-1083.
76.
Amundsen T, Ueland PM, Waage A.Plasma homocysteine levels in patients with deep venous thrombosis. Arterioscler Thromb Vasc Biol1995;15:1321-1323.
77.
Fermo I, Vigano’ D’Angelo S, Paroni R, et al.Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med1995;123:747-753.
78.
den Heijer M, Blom HJ, Gerrits WB, et al.Is hyperhomocysteinemia a risk factor for recurrent venous thrombosis?Lancet1995;345:882-885.
79.
Cattaneo M, Martinelli I, Mannucci PM.Hyperhomocysteinemia as a risk factor for deep vein thrombosis. N Engl J Med1996;335:974-975.
80.
Simioni P, Prandoni P, Burlina A, et al.Hyperhomocysteinemia and deep vein thrombosis. Thromb Haemost1996;76:883-886.
81.
Ridker PM, Hennekens CH, Selhub J, et al.Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation1997;95:1777-1782.
82.
Eichinger S, Stumpflen A, Hirschl M, et al.Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost1998;80:566-569.
83.
Willems HPG, den Heijer M, Bos GMG. Homocysteine and venous thrombosis. Outline of a vitamin intervention trial. Semin Thromb Hemost2000;26:297-304.
84.
den Heijer M, Rosendaal FR, Blom HJ, et al.Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost1988;80:874-877.
85.
Ray JG.Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med1998;158:2101-2206.
86.
Petri M, Roubenoff R, Dallol GE, Nadeau MR, Selhub J, Rosenburg IH.Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet1996;348:1120-1124.
87.
Chauveau P, Chadefaux B, Conde M, et al.Long term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine level in chronic renal failures. Miner Electrolyte Metab1996;22:106-109.
88.
Abou-Gazala T, Lobo A, Alsous F, et al.High plasma homocysteine in patients with coronary artery disease can be reduced by folic acid supplementation. J Am Coll Cardiol1997;27(Suppl 2A):488A.
89.
Malinow MR, Nieto FJ, Kruger WD, et al.The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolase reductase genotypes. Arterioscler Thromb Vasc Biol1997;17:1157-1162.
90.
Landgren F, Israelsson B, Lindgren A, et al.Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect of folic acid. J Intern Med1995;237:381-388.
91.
Ubbink JB, Vermaak WJ, Vander Merwe A, et al.Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr1994;124:1927-1933.
92.
Brattstrom LE, Israelsson B, Jeppsson JO, et al.Folic acid—an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest1988;48:215-221.
93.
Homocysteine lowering trialists’ collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomized trials. Br Med J1998;316:894-898.
94.
Malinow MR, Duell PB, Hess DL, et al.Reduction of plasma homocysteine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med1998;338:1009-1015.
95.
Jacques PF, Selhub J, Bostom AG, et al.The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med1999;340:1449-1454.
96.
Mohr DN, Silverstein MD, Heit JD, et al.The venous stasis syndrome after deep vein thrombosis or pulmonary embolism: a population based study. Mayo Clin Proc2000;75:1249-1256.
